Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Low Back Pain Pipeline Drugs Market Report Overview

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, injury, aging, arthritis, illness, and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such as NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Key Mechanism of Actions ·       Prostaglandin G/H Synthase 2 Inhibitor

·       Prostaglandin G/H Synthase 1 Inhibitor

·       Cannabinoid Receptor 1 Agonist

·       Cannabinoid Receptor 2 Agonist

·       Mu Type Opioid Receptor Agonist

Key Targets ·       Prostaglandin G/H Synthase 2

·       Prostaglandin G/H Synthase 1

·       Mu Type Opioid Receptor

·       Alpha 2 Adrenergic Receptor

·       Cannabinoid Receptor 1

Key Routes of Administration ·       Oral

·       Intravenous

·       Intramuscular

·       Topical

·       Buccal

Key Molecule Types ·       Small Molecule

·       Cell Therapy

·       Oligonucleotide

·       Synthetic Peptide

Key Companies ·       Allodynic Therapeutics LLC

·       Adynxx Inc

·       Amplicore Inc

·       Axsome Therapeutics Inc

·       BioRestorative Therapies Inc

·       Bol Pharma

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

The Low Back Pain drugs in development market research report provides comprehensive information on the therapeutics under development for Low Back Pain, complete with an analysis of products by stage of development, target, and indication. It also provides a market assessment by mechanisms of action (MoA), route of administration (RoA), and molecule type. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.

Low Back Pain Pipeline Drugs Market Segmentation by Target

The key targets in the Low Back Pain pipeline drugs market are Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Mu Type Opioid Receptor, Alpha 2 Adrenergic Receptor, and Cannabinoid Receptor 1 among others. The majority of the pipeline drugs were Prostaglandin G/H Synthase 2 in 2022.

Low Back Pain Pipeline Drugs Market Analysis, by Target, 2022 (%)

Low Back Pain Pipeline Drugs Market Analysis, by Target, 2022 (%) Buy Full Report for More Target Insights Into The Low Back Pain Pipeline Drugs Market, Download a Free Report Sample

Low Back Pain Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the low back pain pipeline drugs market are Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, and Mu Type Opioid Receptor Agonist among others. Prostaglandin G/H Synthase 2 Inhibitor led the market in 2022.

Low Back Pain Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022 (%)

Low Back Pain Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022 (%)

Buy Full Report for More MoA Insights into The Low Back Pain Pipeline Drugs Market, Download a Free Report Sample

Low Back Pain Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Low Back Pain pipeline drugs market are intravenous, intramuscular, topical, buccal, and oral among others. Most of the pipeline drugs followed the oral route of administration in 2022.

Low Back Pain Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

Low Back Pain Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

Buy Full Report for More Routes of Administration Insights into The Low Back Pain Pipeline Drugs Market, Download a Free Report Sample

Low Back Pain Pipeline Drugs Market Segmentation by Molecule Types

The leading molecule types in the Low Back Pain pipeline drugs market are small molecule, cell therapy, oligonucleotide, and synthetic peptide. The small molecule was the leading molecule type in the pipeline in 2022.

Low Back Pain Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)

Low Back Pain Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)

Buy Full Report for More Molecule Type Insights Into The Low Back Pain Pipeline Drugs Market, Download a Free Report Sample

Low Back Pain Pipeline Drugs Market - Competitive Landscape

There companies involved in the development of low back pain drugs in the market are Allodynic Therapeutics LLC, Adynxx Inc, Amplicore Inc, Axsome Therapeutics Inc, BioRestorative Therapies Inc, and Bol Pharma among others. Allodynic Therapeutics LLC has the highest number of products under development among all these companies.

Low Back Pain Pipeline Drugs Market Analysis by Key Companies, 2022 (%)

Low Back Pain Pipeline Drugs Market Analysis by Key Companies, 2022 (%)

Buy Full Report to Know More About The Low Back Pain Pipeline Drugs Market Companies, Download a Free Report Sample

Segments Covered in the Report

Low Back Pain Pipeline Drugs Market MoA Outlook

  • Prostaglandin G/H Synthase 2 Inhibitor
  • Prostaglandin G/H Synthase 1 Inhibitor
  • Cannabinoid Receptor 1 Agonist
  • Cannabinoid Receptor 2 Agonist
  • Mu Type Opioid Receptor Agonist

Low Back Pain Pipeline Drugs Market Target Outlook

  • Prostaglandin G/H Synthase 2
  • Prostaglandin G/H Synthase 1
  • Mu Type Opioid Receptor
  • Alpha 2 Adrenergic Receptor
  • Cannabinoid Receptor 1

Low Back Pain Pipeline Drugs Market RoA Outlook

  • Oral
  • Intravenous
  • Intramuscular
  • Topical
  • Buccal

Low Back Pain Pipeline Drugs Market Molecule Types Outlook

  • Small Molecule
  • Cell Therapy
  • Oligonucleotide
  • Synthetic Peptide

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Ache Laboratorios Farmaceuticos SA
Adynxx Inc
Allodynic Therapeutics LLC
Amplicore Inc
AnGes Inc
Axsome Therapeutics Inc
BioRestorative Therapies Inc
Bol Pharma
Camurus AB
Causeway Therapeutics Ltd
Creative Medical Technology Holdings Inc
Daewon Pharmaceutical Co Ltd
DongKoo Bio & Pharma Co Ltd
Eli Lilly and Co
Epione Therapeutics BV
Ethismos Research Inc
Evero Health Ltd
Gador SA
Hisamitsu Pharmaceutical Co Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Indaptus Therapeutics Inc
Laboratorios Silanes SA de CV
MD Biosciences GmbH
Mesoblast Ltd
Navipharm Co Ltd
Neumentum Inc
Pacira BioSciences Inc
Panacea Biotec Ltd
Persica Pharmaceuticals Ltd
Pfizer Inc
Rebus Holdings Inc
Scilex Holding Co
Sclnow Biotechnology Co Ltd
Shionogi & Co Ltd
Spine BioPharma LLC
Stayble Therapeutics AB
Sun Pharma Advanced Research Company Ltd
Tris Pharma Inc
Valenta Pharm
Vertanical GmbH
WEX Pharmaceuticals Inc
Xgene Pharmaceutical Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Low Back Pain – Overview

Low Back Pain – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Low Back Pain – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Low Back Pain – Companies Involved in Therapeutics Development

Low Back Pain – Drug Profiles

Low Back Pain – Dormant Projects

Low Back Pain – Discontinued Products

Low Back Pain – Product Development Milestones

Featured News & Press Releases

Jun 30, 2022: BioRestorative Therapies announces first patient enrolled for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)

Jun 22, 2022: BioRestorative Therapies announces clinical trial contract with second site for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)

Jun 13, 2022: BioRestorative Therapies announces clinical site initiation for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)

Apr 29, 2022: BioRestorative Therapies hosts principal investigator meeting for its BRTX-100 phase 2 clinical trial to treat chronic lumbar disc disease

Apr 18, 2022: BioRestorative Therapies announces selection of 10 clinical sites for its phase 2 clinical trial to treat chronic lumbar disc disease

Apr 04, 2022: BioRestorative Therapies announces cGMP Cell Manufacturing Facility Certification

Feb 16, 2022: Biorestorative Therapies announces notice of allowance on key patent for its BRTX-100 disc program

Feb 07, 2022: BioRestorative Therapies announces it has initiated its phase 2 clinical trial to treat chronic lumbar disc disease

Jan 04, 2022: BioRestorative Therapies awarded an STTR phase I grant to explore the therapeutic effects of PEG-Peptide hydrogel-encapsulated hypoxic bone marrow stem cells

Aug 20, 2021: Notification of application for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan

Aug 19, 2021: BioRestorative Therapies awarded one of top 10 spine device companies by MedTech Outlook

Jun 30, 2021: Mesoblast provides update on program for chronic low back pain due to degenerative disc disease

Feb 17, 2021: AnGes’ phase 1b results of NF-kappa B Oligo DNA Decoy administration in subjects with chronic discogenic low back pain support advancement into phase 2 clinical study

Feb 10, 2021: Mesoblast phase 3 trial shows that a single injection of Rexlemestrocel-L + Hyaluronic Acid carrier results in at least two years of pain reduction with opioid sparing activity in patients with chronic low back pain due to degenerative disc disease

Dec 07, 2020: Notification of the results of Phase clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Low Back Pain, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Low Back Pain – Pipeline by Ache Laboratorios Farmaceuticos SA, 2022

Low Back Pain – Pipeline by Adynxx Inc, 2022

Low Back Pain – Pipeline by Allodynic Therapeutics LLC, 2022

Low Back Pain – Pipeline by Amplicore Inc, 2022

Low Back Pain – Pipeline by AnGes Inc, 2022

Low Back Pain – Pipeline by Axsome Therapeutics Inc, 2022

Low Back Pain – Pipeline by BioRestorative Therapies Inc, 2022

Low Back Pain – Pipeline by Bol Pharma, 2022

Low Back Pain – Pipeline by Camurus AB, 2022

Low Back Pain – Pipeline by Causeway Therapeutics Ltd, 2022

Low Back Pain – Pipeline by Creative Medical Technology Holdings Inc, 2022

Low Back Pain – Pipeline by Daewon Pharmaceutical Co Ltd, 2022

Low Back Pain – Pipeline by DongKoo Bio & Pharma Co Ltd, 2022

Low Back Pain – Pipeline by Eli Lilly and Co, 2022

Low Back Pain – Pipeline by Epione Therapeutics BV, 2022

Low Back Pain – Pipeline by Ethismos Research Inc, 2022

Low Back Pain – Pipeline by Evero Health Ltd, 2022

Low Back Pain – Pipeline by Gador SA, 2022

Low Back Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022

Low Back Pain – Pipeline by Imbrium Therapeutics LP, 2022

Low Back Pain – Pipeline by Immune Pharmaceuticals Inc, 2022

Low Back Pain – Pipeline by Indaptus Therapeutics Inc, 2022

Low Back Pain – Pipeline by Laboratorios Silanes SA de CV, 2022

Low Back Pain – Pipeline by MD Biosciences GmbH, 2022

Low Back Pain – Pipeline by Mesoblast Ltd, 2022

Low Back Pain – Pipeline by Navipharm Co Ltd, 2022

Low Back Pain – Pipeline by Neumentum Inc, 2022

Low Back Pain – Pipeline by Pacira BioSciences Inc, 2022

Low Back Pain – Pipeline by Panacea Biotec Ltd, 2022

Low Back Pain – Pipeline by Persica Pharmaceuticals Ltd, 2022

Low Back Pain – Pipeline by Pfizer Inc, 2022

Low Back Pain – Pipeline by Rebus Holdings Inc, 2022

Low Back Pain – Pipeline by Scilex Holding Co, 2022

Low Back Pain – Pipeline by Sclnow Biotechnology Co Ltd, 2022

Low Back Pain – Pipeline by Shionogi & Co Ltd, 2022

Low Back Pain – Pipeline by Spine BioPharma LLC, 2022

Low Back Pain – Pipeline by Stayble Therapeutics AB, 2022

Low Back Pain – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022

Low Back Pain – Pipeline by Tris Pharma Inc, 2022

Low Back Pain – Pipeline by Valenta Pharm, 2022

Low Back Pain – Pipeline by Vertanical GmbH, 2022

Low Back Pain – Pipeline by WEX Pharmaceuticals Inc, 2022

Low Back Pain – Pipeline by Xgene Pharmaceutical Inc, 2022

Low Back Pain – Dormant Projects, 2022

Low Back Pain – Dormant Projects, 2022 (Contd..1)

Low Back Pain – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Low Back Pain, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.